JP2017169559A5 - - Google Patents

Download PDF

Info

Publication number
JP2017169559A5
JP2017169559A5 JP2017037848A JP2017037848A JP2017169559A5 JP 2017169559 A5 JP2017169559 A5 JP 2017169559A5 JP 2017037848 A JP2017037848 A JP 2017037848A JP 2017037848 A JP2017037848 A JP 2017037848A JP 2017169559 A5 JP2017169559 A5 JP 2017169559A5
Authority
JP
Japan
Prior art keywords
antibody
seq
cell
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017037848A
Other languages
English (en)
Other versions
JP2017169559A (ja
JP6334763B6 (ja
JP6334763B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017169559A publication Critical patent/JP2017169559A/ja
Publication of JP2017169559A5 publication Critical patent/JP2017169559A5/ja
Application granted granted Critical
Publication of JP6334763B2 publication Critical patent/JP6334763B2/ja
Publication of JP6334763B6 publication Critical patent/JP6334763B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (22)

  1. 新生児FcRnレセプター(FcRn)に特異的な抗体を製造する方法であって、
    (i)プロモーターにそれぞれ機能可能に連結している、該抗体の軽鎖可変領域(V )をコードする第1の核酸および該抗体の重鎖可変領域(V )をコードする第2の核酸を含む宿主細胞を培養し、該抗体を生産する工程;および
    (ii)工程(i)で生産された抗体を回収する工程;
    を含み、
    ここで、該Vは、
    アミノ酸配列TGTGSDVGSYNLVS(配列番号14)を含むV CDR1、
    アミノ酸配列GDSQRPS(配列番号15)を含むV CDR2、および
    アミノ酸配列SSYAGSGIYV(配列番号12)またはASYAGSGIYV(配列番号13)を含むV CDR3を含み、かつ、
    該Vは、
    アミノ酸配列EYAMG(配列番号22)を含むV CDR1、
    アミノ酸配列SIGSSGGQTKYADSVKG(配列番号23)を含むV CDR2、
    アミノ酸配列LAIGDSY(配列番号24)を含むV CDR3を含む、
    方法
  2. が、配列番号10または配列番号11と少なくとも85%の相同性を有するアミノ酸配列を含む、請求項1に記載の方法
  3. が、配列番号10または配列番号11のアミノ酸配列を含む、請求項2に記載の方法
  4. が、配列番号9と少なくとも85%同一であるアミノ酸配列を含む、請求項1〜3のいずれか一項に記載の方法
  5. が配列番号9のアミノ酸配列を含む、請求項4に記載の方法
  6. 前記第2の核酸が、配列番号17のC末端リジン残基に対応する位置に欠失を有する、重鎖定常領域(C )をさらにコードする、請求項1〜5のいずれか一項記載の方法
  7. 前記 配列番号26のアミノ酸配列を含む、請求項6に記載の方法
  8. 前記抗体が、10nM未満の解離定数(K)でヒトFcRnと結合する、請求項1〜のいずれか一項に記載の方法
  9. 前記抗体が、完全長抗体である、請求項1〜のいずれか一項に記載の方法
  10. 前記抗体が、ヒト抗体もしくはヒト化抗体であるか、または、ヒトにおいて非免疫原性である、請求項1〜のいずれか一項に記載の方法
  11. 前記抗体が、ヒト抗体フレームワーク領域を含む、請求項1〜1のいずれか一項に記載の方法
  12. 前記抗体が、マウス抗体である、請求項1〜のいずれか一項に記載の方法
  13. 前記抗体が、キメラ抗体である、請求項1〜9のいずれか一項に記載の方法
  14. 前記抗体が、Fab、F(ab)'2、Fv、およびscFvからなる群から選択される、請求項1〜のいずれか一項に記載の方法
  15. 前記抗体が、モノクローナル抗体である、請求項1〜14のいずれか一項に記載の方法
  16. 前記第1の核酸および前記第2の核酸が、同じ発現ベクター上にある、請求項1〜15のいずれか一項記載の方法。
  17. 前記第1の核酸および前記第2の核酸が、2つの異なる発現ベクター上にある、請求項1〜15のいずれか一項記載の方法。
  18. 前記宿主細胞が、菌細胞、酵母細胞、昆虫細胞、植物細胞、または哺乳類細胞である、請求項1〜17のいずれか一項記載の方法。
  19. 前記宿主細胞が、哺乳類細胞である、請求項18記載の方法。
  20. 前記哺乳類細胞が、チャイニーズハムスター卵巣(CHO細胞)、NS0骨髄腫細胞、SP2細胞、COS細胞、および乳腺上皮細胞からなる群から選択される、請求項19記載の方法。
  21. 前記宿主細胞が、内因性のジヒドロ葉酸還元酵素を欠いている(dhfr )、請求項20記載の方法。
  22. 前記第1の核酸または前記第2の核酸が、DHFRタンパク質をさらにコードする、請求項21記載の方法。
JP2017037848A 2011-06-02 2017-03-01 Fcレセプター結合タンパク質 Active JP6334763B6 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161492617P 2011-06-02 2011-06-02
US61/492,617 2011-06-02
US201161498266P 2011-06-17 2011-06-17
US61/498,266 2011-06-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014513732A Division JP6104897B2 (ja) 2011-06-02 2012-06-01 Fcレセプター結合タンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018085040A Division JP6638018B2 (ja) 2011-06-02 2018-04-26 Fcレセプター結合タンパク質

Publications (4)

Publication Number Publication Date
JP2017169559A JP2017169559A (ja) 2017-09-28
JP2017169559A5 true JP2017169559A5 (ja) 2017-12-07
JP6334763B2 JP6334763B2 (ja) 2018-05-30
JP6334763B6 JP6334763B6 (ja) 2018-07-11

Family

ID=47259886

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014513732A Active JP6104897B2 (ja) 2011-06-02 2012-06-01 Fcレセプター結合タンパク質
JP2017037848A Active JP6334763B6 (ja) 2011-06-02 2017-03-01 Fcレセプター結合タンパク質
JP2018085040A Active JP6638018B2 (ja) 2011-06-02 2018-04-26 Fcレセプター結合タンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014513732A Active JP6104897B2 (ja) 2011-06-02 2012-06-01 Fcレセプター結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018085040A Active JP6638018B2 (ja) 2011-06-02 2018-04-26 Fcレセプター結合タンパク質

Country Status (14)

Country Link
US (6) US9359438B2 (ja)
EP (2) EP2714084B1 (ja)
JP (3) JP6104897B2 (ja)
KR (1) KR102014554B1 (ja)
CN (2) CN103619353B (ja)
AU (2) AU2012262007B2 (ja)
BR (1) BR112013030352B1 (ja)
CA (1) CA2837527C (ja)
ES (1) ES2748583T3 (ja)
HK (2) HK1195260A1 (ja)
IL (1) IL229618B (ja)
MX (1) MX343659B (ja)
SG (2) SG195025A1 (ja)
WO (1) WO2012167039A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101837329B1 (ko) * 2008-04-25 2018-03-09 다이액스 코포레이션 Fcrn에 대한 항체 및 이들의 용도
CA2837527C (en) 2011-06-02 2019-05-28 Dyax Corp. Fc receptor binding proteins
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
EP4053560A1 (en) 2013-11-26 2022-09-07 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
MX2016014210A (es) * 2014-04-30 2017-05-01 Hanall Biopharma Co Ltd Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
LT3250610T (lt) * 2015-01-30 2023-09-25 Momenta Pharmaceuticals, Inc. Fcrn antikūnai ir jų panaudojimo būdai
EA201892427A1 (ru) 2016-04-25 2019-10-31 ГУМАНИЗИРОВАННЫЕ АНТИ-FcRn АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ
SG11201900813RA (en) * 2016-07-29 2019-02-27 Momenta Pharmaceuticals Inc Fcrn antibodies and methods of use thereof
EP3548320B1 (en) 2016-12-01 2022-12-07 SABIC Global Technologies B.V. Hybrid composite tailgate
AU2018386193A1 (en) 2017-12-13 2020-06-25 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
KR20210105873A (ko) * 2018-07-20 2021-08-27 모멘타 파머슈티컬스 인코포레이티드 Fcrn 항체 조성물
KR20220050127A (ko) * 2019-07-23 2022-04-22 상하이테크 유니버시티 Asic1 채널 안타고니스트 항체
JP2023531451A (ja) 2020-06-17 2023-07-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 遺伝子療法患者の治療のための組成物及び方法
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ES2035317T5 (es) 1987-11-09 1998-03-16 Becton Dickinson Co Metodo para analizar celulas hematopoyeticas en una muestra.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
KR100566859B1 (ko) 1997-01-21 2006-04-03 제너럴 하스피톨 코포레이션 Rna-단백질 융합물을 이용한 단백질의 선별
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
IL138668A0 (en) 1998-04-03 2001-10-31 Phylos Inc Addressable protein arrays
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
ATE434040T1 (de) 2001-10-01 2009-07-15 Dyax Corp Mehrkettige eukaryontische display-vektoren und deren verwendungen
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
CA2478169C (en) 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
JP2007501847A (ja) * 2003-08-08 2007-02-01 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己/同種免疫状態の治療用抗FcRn抗体
JP2008538919A (ja) * 2005-04-29 2008-11-13 ザ ジャクソン ラボラトリー FcRn抗体およびその使用
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
US20070181136A1 (en) 2006-02-08 2007-08-09 Gelb Michael L Oral appliance
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
MX2010003450A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
KR101837329B1 (ko) 2008-04-25 2018-03-09 다이액스 코포레이션 Fcrn에 대한 항체 및 이들의 용도
US8537763B2 (en) 2008-06-30 2013-09-17 Motorola Mobility Llc Frame allocation to support legacy wireless communication protocols on uplink transmission
WO2010008051A1 (ja) * 2008-07-16 2010-01-21 株式会社医学生物学研究所 抗ヒトclcp1抗体とその用途
UY32341A (es) * 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
WO2010107110A1 (ja) * 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
CA2837527C (en) 2011-06-02 2019-05-28 Dyax Corp. Fc receptor binding proteins
US11149094B2 (en) 2017-06-05 2021-10-19 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
MA52790A (fr) 2018-06-08 2021-04-14 Argenx Bvba Compositions et méthodes de traitement de la thrombopénie immune

Similar Documents

Publication Publication Date Title
JP2017169559A5 (ja)
US20230242651A1 (en) Stable antibody variable domain framework combinations
HRP20201993T1 (hr) Protutijela protiv pd-1
JP2020508655A5 (ja)
JP2020504101A5 (ja)
JP2020519308A5 (ja)
KR102286053B1 (ko) 신규한 항체 기본구조
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
CN104968685A (zh) 异源二聚免疫球蛋白的纯化
US11319371B2 (en) Anti-CD3 antibodies
RU2011153932A (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Toll-ПОДОБНЫМ РЕЦЕПТОРАМ 2 И ИХ ПРИМЕНЕНИЯ
JP2023088986A (ja) カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用
JP2018121657A5 (ja)
HRP20131215T1 (hr) Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope
JP2020524510A5 (ja)
JP2012514997A5 (ja)
JP2019504617A5 (ja)
JP2012531922A5 (ja) Toll様受容体2へのヒト化抗体またはその抗原結合部位
HRP20220787T1 (hr) Protutijela protiv garp-tgf-beta
RU2013119957A (ru) Человеческие антитела к онкостатину м и способы их применения
RU2012122203A (ru) Композиции и способы для лечения восполительных нарушений
JP2015508056A5 (ja)
JP2016518333A5 (ja)
WO2018224441A1 (en) Novel anti-cd3 antibodies
US11365240B2 (en) Anti-HSA antibodies